Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MESOBullishCorporate Developmentsnews

High materiality8/10

Mesoblast Advances Rexlemestrocel-L CLBP Trial Toward 2027 Readout with RMAT Benefits

Jul 13, 2026, 8:37 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Direct trial progress and RMAT-regulatory pathway improvement strengthen odds of near-term value inflection; readout timing is a discrete event.

AI summary

What happened, with direct paths to the underlying reporting

Mesoblast announced it has met its target of at least 300 patients in the MSB-DR004 pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain due to degenerative disc disease. Top-line results are expected in mid-2027 after 12 months of follow-up, with RMAT designation potentially expediting review after a BLA filing. A potential US peak revenue above $10B with single-digit penetration underpins upside.

Mesoblast hits target of ≥300 patients in MSB-DR004 pivotal CLBP trial.
RMAT designation supports priority review; top-line results due mid-2027.
CLBP is a large US market; potential peak revenue >$10B.
Manufacturing scaling underway; plan to file BLA after readout.
Primary endpoint: 12-month pain reduction; secondary QoL, function, opioid cessation.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Mesoblast Advances Rexlemestrocel-L CLBP Trial Toward 2027 Readout with RMAT Benefits

Mesoblast completes Phase 3 CLBP treatment; readout expected in 2027

Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges